Australia is gain access to potentially transformative therapy for obesity: Retatrutide. The dual agonist – working on both GLP-1 and GIP receptors – has remarkable results in international research, pointing to meaningful reductions in weight. While regulatory clearance remains with TGA, a number of individuals battling obesity could hoping fo… Read More